Literature DB >> 28711998

Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS).

Thomas Kuczmarski1, Elijah W Stommel1, Kristen Riley2, Rup Tandan3, Vinay Chaudhry2, Lora Clawson2, Tracie A Caller4, Patricia L Henegan1, Dominic N Facciponte1, Walter G Bradley5, Angeline S Andrew6.   

Abstract

A recent population-based analysis demonstrated lower risk of the lethal degenerative neuromuscular disease, amyotrophic lateral sclerosis (ALS) associated with history of the use of 'antineoplastic agents' and 'immunosuppressants'. To see if this finding was generalizable to other ALS cohorts, we examined associations between use of these agents and ALS risk in an independent case-control study of n = 414 ALS patients and n = 361 controls in an Eastern US population. Controls were sampled from the general population and among non-neurodegenerative disease patients. A history of chemotherapy treatment was significantly associated with a decreased ALS risk (OR 0.46, 95% CI 0.22-0.89, P = 0.026). We did not observe an association between risk of ALS and immunosuppressant therapy use (OR 0.78, 95% CI 0.50-1.02, P = 0.23). Analyses were adjusted for age, gender, and smoking. Our results support the prior report for chemotherapy treatment and lead to further discussion of the underlying mechanism.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Case–control; Chemotherapy; Immunosuppressant; Neurodegenerative

Mesh:

Substances:

Year:  2017        PMID: 28711998     DOI: 10.1007/s00415-017-8564-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

Review 1.  Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review.

Authors:  João Costa; Michael Swash; Mamede de Carvalho
Journal:  Arch Neurol       Date:  2012-11

2.  Interaction of cisplatin with human superoxide dismutase.

Authors:  Lucia Banci; Ivano Bertini; Olga Blaževitš; Vito Calderone; Francesca Cantini; Jiafei Mao; Angela Trapananti; Miguela Vieru; Ilaria Amori; Mauro Cozzolino; Maria Teresa Carrì
Journal:  J Am Chem Soc       Date:  2012-04-12       Impact factor: 15.419

Review 3.  Apoptosis in amyotrophic lateral sclerosis--what is the evidence?

Authors:  Sivakumar Sathasivam; Pamela J Shaw
Journal:  Lancet Neurol       Date:  2005-08       Impact factor: 44.182

4.  The association between cancer and amyotrophic lateral sclerosis.

Authors:  D Michal Freedman; Rochelle E Curtis; Sarah E Daugherty; James J Goedert; Ralph W Kuncl; Margaret A Tucker
Journal:  Cancer Causes Control       Date:  2012-10-23       Impact factor: 2.506

5.  Amyotrophic lateral sclerosis mortality in 1.9 million US cancer survivors.

Authors:  D Michal Freedman; Lois B Travis; Gloria Gridley; Ralph W Kuncl
Journal:  Neuroepidemiology       Date:  2005-08-15       Impact factor: 3.282

6.  The risk of amyotrophic lateral sclerosis after cancer in U.S. elderly adults: a population-based prospective study.

Authors:  D Michal Freedman; Jincao Wu; Sarah E Daugherty; Ralph W Kuncl; Lindsey R Enewold; Ruth M Pfeiffer
Journal:  Int J Cancer       Date:  2014-02-28       Impact factor: 7.396

7.  Prior medical conditions and the risk of amyotrophic lateral sclerosis.

Authors:  Meinie Seelen; Perry T C van Doormaal; Anne E Visser; Mark H B Huisman; Margot H J Roozekrans; Sonja W de Jong; Anneke J van der Kooi; Marianne de Visser; Nicol C Voermans; Jan H Veldink; Leonard H van den Berg
Journal:  J Neurol       Date:  2014-07-25       Impact factor: 4.849

Review 8.  Is there a paraneoplastic ALS?

Authors:  Philippe Corcia; Paul H Gordon; Jean-Philippe Camdessanche
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-10-06       Impact factor: 4.092

9.  Population-based risks for cancer in patients with ALS.

Authors:  Summer B Gibson; Diana Abbott; James M Farnham; Khanh K Thai; Hailey McLean; Karla P Figueroa; Mark B Bromberg; Stefan M Pulst; Lisa Cannon-Albright
Journal:  Neurology       Date:  2016-05-11       Impact factor: 9.910

10.  Is the risk of motor neuron disease increased or decreased after cancer? An Australian case-control study.

Authors:  Alex Stoyanov; Roger Pamphlett
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

View more
  1 in total

1.  Medication use and risk of amyotrophic lateral sclerosis-a systematic review.

Authors:  Can Cui; Jiangwei Sun; Kyla A McKay; Caroline Ingre; Fang Fang
Journal:  BMC Med       Date:  2022-08-05       Impact factor: 11.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.